Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma Biotech Investing
Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018 Pharmaceutical Investing
Molecular Templates Announces Agreement with Takeda for the Joint Development of a Protein-Based Oncology Therapy Genetics Investing
